Administered 30-60 minutes before bedtime at doses of 250-300mcg for most users, the peptide amplifies nocturnal growth hormone pulses that drive deep sleep onset and maintenance, creating measurable improvements in sleep architecture including increased slow-wave sleep percentage, reduced sleep fragmentation, faster sleep onset, and dramatically enhanced subjective experience of more refreshing rest
No baseline to measure against
Rodriguez-Segade S, Alonso de la Pea C, Paz M, Novoa D, Romero R, Arcocha V et al (1986) Carnitine concentrations in dialysed and undialysed patients with chronic renal insufficiency
FDA Approval Status: The Unapproved Drug Classification Is BPC-157 FDA-approved for human use
10.1038/s41598-018-25516-3 173 StevenS.FrenisK.OelzeM.KalinovicS.KunticM.Bayo JimenezM